ALXN1850, Strensiq 40 mg/ml Solution for Injection, Strensiq 100 mg/ml Solution for Injection
ALXN1850-HPP-303
Phase 3 small_molecule active
Quick answer
ALXN1850, Strensiq 40 mg/ml Solution for Injection, Strensiq 100 mg/ml Solution for Injection for Hypophosphatasia is a Phase 3 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alexion Europe SAS
- Indication
- Hypophosphatasia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active